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LETTERS TO THE EDITOR 
Coumadin and the St. Jude Valve Prosthesis 
Since the publication of our article on the St. Jude valve prosthesis 
(1) and the need for systemic anticoagulation, there have been a 
number of inquiries regarding whether the need for anticoagulation 
demonstrated by our data was similar for aortic and mitral valve 
prostheses. Our data indicated a significant excess risk of thrombo- 
embolic complications for patients who were not receiving warfarin 
(Coumadin). This risk was significant for both mitral and aortic 
prostheses. Furthermore, the risk of a serious hemorrhagic compli- 
cation was equally low for both mitral and aortic prostheses. 
The data in the table herein are similar to those shown in Table 
2 of the original article, but are divided for mitral and aortic valves 
separately. It should be noted that the data from double valve 
replacements have not been tabulated and therefore the totals in 
Table 2 of the publication do not correspond precisely to the totals 
of the isolated aortic and mitral valve data. 
I believe that publication of these data may resolve existing 
doubt as to the need for Coumadin in patients with an isolated aortic 
St. Jude prosthesis. The data suggest that all patients receiving an 
aortic or mitral St. Jude prosthesis should receive Coumadin anti- 
coagulant therapy unless a contraindication to such therapy exists. 
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Table 1. Incidence of Thromboembolic Events According to the 
Anticoagulant Regimen Present at the Time of the Event for 
Isolated Aortic and Isolated Mitral Valve Replacements 
Warfarin Antiplatelet None Total 
Isolated aortic 
Months on each therapy 
No. of observed events 
No. of expected events 
Isolated mitral 
Months on each therapy 
No. of observed events 
No. of expected events 
9,554 1,916 
16 10 
25.1 5.03 
x' = 28.1, 
p=o.ooo1 
4,896 502 
16 8 
21.5 2.21 
,$ = 16.9, 
p=o.OlN2 
One event in a double valve replacement is excluded. 
Stone et al. (I) report a higher rate of intraventricular conduction 
delay in the diabetic group during hospitalization as compared with 
the nondiabetic group (23.5% versus 13.0%). However, no differ- 
ence was found in both groups (diabetic and nondiabetic) in the 
incidence of atrial premature depolarization and ventricular fibrilla- 
tion. We (12) reported conduction and rhythm disturbances as well 
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321 11,791 
5 31 
0.84 - 
63 5,461 
0 24 
0.28 - 
Ischemic Heart Disease and Diabetic 
Cardiomyopathy 
Stone et al. (1) bring new data supporting the accepted evidence that 
patients with diabetes mellitus have a higher morbidity and mortality 
after acute myocardial infarction as compared with patients with 
acute myocardial infarction free of diabetes mellitus. 
The authors related these findings to an acceleration of the 
atherosclerotic process or to diabetic cardiomyopathy, or both. 
However, the diagnosis of diabetic cardiomyopathy could be con- 
sidered only in those diabetic patients in whom coronary atheroscle- 
rotic heart disease. hypertensive cardiovascular disease or other 
etiologic factors causing myocardial dysfunction have been elimi- 
nated (2-4). All patients included in this study presented with 
ischemic heart disease; some had hypertension. Hence, they could 
not be considered as having diabetic cardiomyopathy (5,6). Further- 
more, the terms diabetic cardiomyopathy and cardiomyopathic 
process are interchangeably used by the authors and represent two 
separate histopathologic entities. For instance, the ischemic process 
existent in all patients may lead to ischemic cardiomyopathy-a 
term first used by Burch and colleagues (7) and accepted by most of 
the authors of classic textbooks (8,9). From the practical standpoint, 
ischemic cardiomyopathy is manifested by severe myocardial dys- 
function often caused by multiple infarctions and severe heart 
failure whereas diabetic cardiomyopathy is a more benign cardio- 
myopathy because of lack of occlusion of the epicardial coronary 
arteries. Infants born of diabetic mothers may present a transient 
cardiomyopathy mostly with septal hypertrophy and right ventricu- 
lar free wall hypertrophy (10). 
In this study (l), the distribution and rate of progression of 
coronary atherosclerosis could not be objectively assessed. The 
poor outcome among patients with diabetes during the in-hospital 
phase and among hospital survivors might have been caused by 
acceleration of the atherosclerotic process. Further angiographic 
studies might confirm this supposition. 
The authors (1) included left ventricular diastolic dysfunction 
among the main contributing factors to the adverse prognosis in 
diabetic patients. Previous experimental and clinical studies and, 
more recently, two-dimensional Doppler echocardiographic studies 
(6,ll) confirmed that diastolic left ventricular dysfunction appears 
early in diabetic cardiomyopathy (in subjects with diabetes with no 
history or symptoms of coronary artery involvement, hypertension 
or valvular disease). On the other hand, diastolic left ventricular 
function can be affected by ischemia and hypertension, both condi- 
tions considered to be present in both diabetic and nondiabetic 
patients. Therefore, in this study, the presence of diabetes as an 
additional aggravating factor of existent diastolic left ventricular 
dysfunction remains unknown. 
